Join our daily newsletter At The Bell to receive exclusive market insights
- Antisense Therapeutics (ANP) submits its first clinical trial application for the Phase 2b/3 clinical trial of its drug aiming to treat muscular dystrophy
- The application has been submitted to the Federal Institute for Drugs and Medical Devices in Germany for evaluation and approval
- The company says the submission is a milestone moment as it works to establish a regulatory pathway with the European Medicines Agency
- It is working to optimise its capital management process for the drug’s development to ensure effective use of its existing cash reserves
- Shares are trading 1.20 per cent higher today at 8.4 cents each at 11:20 am AEST.
Antisense Therapeutics (ANP) has submitted its first clinical trial application for the Phase 2b/3 clinical trial of ATL1102.
ATL1102 aims to treat patients with muscular dystrophy who are unable to walk.
The application was submitted to the Federal Institute for Drugs and Medical Devices in Germany for evaluation and approval.
The company said the application submission was a milestone moment as it works to establish a regulatory pathway with the European Medicines Agency.
Antisense has been working to optimise its capital management process for the drug’s development to ensure effective use of its existing cash reserves.
Shares were trading 1.20 per cent higher today at 8.4 cents each at 11:20 am AEST.
